•Alcon acquires Neurotech, MacTel therapy Encelto•Stuart Therapeutics submits IND amendment for corneal wound healing•Innovent's Sycume meets phase 3 endpoint for inactive TED•Alcon's Brytly Redness Reliever Drops receive FDA approval•FDA approves RYZUMVI for presbyopia•Alcon acquires Neurotech, MacTel therapy Encelto•Stuart Therapeutics submits IND amendment for corneal wound healing•Innovent's Sycume meets phase 3 endpoint for inactive TED•Alcon's Brytly Redness Reliever Drops receive FDA approval•FDA approves RYZUMVI for presbyopia
HEADLINES
FEATURED
LUCIA trial fails to meet primary goal; company to cut workforce reduction by 53% as part of a strategic prioritization to advance phase 3 DME program.
Earn FREE CE 24/7 with Courses by Eyes On Eyecare
Explore premium-quality, bite-sized courses featuring leading experts like Cecelia Koetting, OD, FAAO, and Cory Lappin, OD, MS, FAAO, and continuing education covering topics from ocular rosacea treatments to retinal disease.
